Medtronic's Stable Outlook and Growth Prospects Reinforce Buy Rating
Mizuho Securities Cuts Price Target on Medtronic to $95 From $98
Medtronic Analyst Ratings
Goldman Sachs Adjusts Price Target on Medtronic to $77 From $83
Medtronic Analyst Ratings
Daiwa Securities Adjusts Price Target on Medtronic to $92 From $100
Medtronic Analyst Ratings
RBC Capital Keeps Their Hold Rating on Medtronic (MDT)
Truist Securities Adjusts Price Target on Medtronic to $88 From $90, Keeps Hold Rating
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Medtronic (MDT) and Cytokinetics (CYTK)
Medtronic Analyst Ratings
Medtronic Poised for Growth: A Buy Rating With Promising Fiscal Projections and Undervalued Stock
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)
Analysts Conflicted on These Healthcare Names: MacroGenics (MGNX) and Medtronic (MDT)
Medtronic's Strong Q4 Performance and Positive FY2025 Outlook Merit Buy Rating
Medtronic Q4 Earnings Analysis: Maintaining Hold Rating Amidst Modest Growth Projections and Margin Pressures
Piper Sandler Adjusts Medtronic's Price Target to $85 From $87, Keeps Neutral Rating
Wells Fargo Sticks to Their Buy Rating for Medtronic (MDT)
Medtronic (MDT) Gets a Buy From Barclays
Stable Growth and Positive Outlook: A Buy Recommendation for Medtronic